Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors

ACS Medicinal Chemistry Letters

Volumn 5, Issue 3, 2014, Pages 240-243

  Giroux, Simon ^a   Xu, Jinwang ^a   Reddy, T Jagadeeswar ^a   Morris, Mark ^a   Cottrell, Kevin M ^a   Cadilhac, Caroline ^a   Henderson, James A ^a   Nicolas, Oliver ^a   Bilimoria, Darius ^a   Denis, Francois ^a   Mani, Nagraj ^a   Ewing, Nigel ^a   Shawgo, Rebecca ^a   L'Heureux, Lucille ^a   Selliah, Subajini ^a   Chan, Laval ^a   Chauret, Nathalie ^a   Berlioz Seux, Francoise ^a   Namchuk, Mark N ^a   Grillot, Anne Laure ^a   Bennani, Youssef L ^a   Das, Sanjoy K ^a   Maxwell, John P ^a   more..

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

HCV; NS5A; Thienoimidazoles

Indexed keywords

ACETYLENE DERIVATIVE; ANTIVIRUS AGENT; BENZIMIDAZOLE; BORONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; NONSTRUCTURAL PROTEIN 5A INHIBITOR;

ANIMAL TISSUE; ARTICLE; CYCLIZATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SYNTHESIS; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HUMAN TISSUE; LIVER MICROSOME; METABOLIC STABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; SONOGASHIRA REACTION; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION;

EID: 84990931466     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300461f     Document Type: Article

References (20)

1. Negro, F.; Alberti, A. The global health burden of hepatitis C virus infection. Liver Int. 2011, 31, 1-3.
2. For reviews, see De Francesco, R.; Migliaccio, G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005, 436, 953.
3. Houghton, M.; Abrignani, S. Prospect for a vaccine against the hepatitis C virus. Nature 2005, 436, 961-966.
4. Feld, J. J.; Hoofnagle, J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436, 967-972.
5. Pearlman, B. L. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Inf. Dis. 2012, 12, 717-728.
6. Chatel-Chaix, L.; Baril, M.; Lamarre, D. Hepatitis C Virus NS3/4A Proteases Inhibitors: A Light at the End of the Tunnel. Viruses 2010, 2, 1752-1765.
7. Chen, K. X.; Njoroge, F. G. A review of HCV protease inhibitors. Curr. Opin. Invest. Drugs 2009, 10, 821-837.
8. Kwong, A. D.; McNair, L.; Jacobson, I.; George, S. Recent progress in the development of selected hepatitis C virus NS3/4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 2008, 8, 522-531.
9. Poordad, F.; Dieterich, D. Treating hepatitis C: Current standard of care and emerging direct-acting antiviral agents. J. Viral Hepatitis 2012, 19, 449-464.
10. Schmitz, U.; Tan, S.-L. NS5A-From Obscurity to New Target for HCV Therapy. Recent Pat. Anti-infect. Drug Discovery 2008, 3, 77-92.
11. Lemm, J. A.; O'Boyle, D., II; Liu, M.; Nower, P. T.; Colonno, R; Deshpande, M. S.; Snyder, L. B.; Martin, S. W.; St. Laurent, D. R; Serrano-Wu, M. H.; Romine, J. L.; Meanwell, N. A.; Gao, M. Identification of Hepatitis C Virus NS5A Inhibitors. J. Virol. 2010, 84, 482-491.
12. Bell, T. W. Drugs for Hepatitis C: Unlocking a New Mechanism of Action. ChemMedChem 2010, 5, 1663-1665.
13. Gao, M.; Nettles, R E.; Belema, M.; Snyder, L. B.; Nguyen, V. N; Fridell, R A.; Serrano-Wu, M. H; Langley, D. R; Sun, J.-H; O'Boyle, D. R, II; Lemm, J. A.; Wang, C.; Knipe, J. O.; Chien, C.; Colonno, R J.; Grasela, D. M.; Meanwell, N. A; Hamann, L. G Chemical genetics strategy identifies an HCV NS5A inhibitor with potent clinical effect. Nature 2010, 465, 96-100.
14. Pereira, O.; Maxwell, J.; Bennani, Y. L.; Das, S. K; Kong, L. C. C.; Reddy, T. J.; Giroux, S.; Cottrell, K M.; Morris, M. A Patent WO / 2011/119858.
15. For the synthesis, see Kong, L. C. C.; Giroux, S.; Reddy, T. J; Bennani, Y. L. Patent WO /2011/119870 and reference therein.
16. For an alternative synthesis of the thienoimidazole core, see Hartley, D. J.; Iddon, B. Use of the Vinyl Group as an Efficient Protecting Group for Azole N-Atoms: Synthesis of Polyfunctionalized Imidazoles and Thieno[2, 3-d]-[3, 2-d]imidazole. Tetrahedron Lett. 1997, 38, 4647-4650.
17. See the Supporting Information for the details of the syntheses of intermediate 6 and compound 20.
18. Large potency drops were observed when 20 was screened against recombinant replicon cell lines harboring some of these mutations: (1a Y93H/C, >15000-fold; 1a M28T and Q30R >500-fold; and 1b Y93H, 900-fold).
19. Fridell, R A; Qui, D.; Wang, C.; Valera, L.; Gao, M. Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System. Antimicrob. Agents Chemother. 2010, 54, 3641-3650.
20. 50 of the positive control was within 40% of the mean value.